SPSurojit Paul

Surojit Paul

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Surojit Paul has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Moderate Prenatal Alcohol Exposure Disrupts Brain Redox Homeostasis and the Activity of Tyrosine Phosphatase STEP in Adult Offspring

    by Anindita Bhattacharjee, Sathyanarayanan Rajagopal, Seong Won Choi, John Weaver, Ke Jian Liu, Ranjana Poddar, Kevin K. Caldwell, C. Fernando Valenzuela, Surojit Paul

    Background: Despite public health efforts, prenatal alcohol exposure (PAE) remains a significant concern. Its effects on offspring vary depending on the amount and frequency of drinking, and the risk of Fetal Alcohol Spectrum Disorders (FASDs) increases with heavy or binge drinking. In contrast, the long‐term consequences of moderate PAE remain unclear. Although previous studies indicate that moderate PAE may have a limited impact on neurodevelopment, its ability to induce persistent cerebrovascular dysfunction may promote chronic low‐level oxidative stress in the brain. Therefore, it is important to determine whether moderate PAE can trigger long‐lasting impairments in brain function that persist into adulthood. Methods: The current study investigated the effect of moderate PAE on the brain's redox environment in adult (4–6 months) and middle‐aged (12–14 months) offspring. Electron paramagnetic resonance (EPR) spectroscopy was used to noninvasively measure thiol levels in the brain. Biochemical assays measured levels of reduced and total glutathione, the primary thiol and major antioxidant in the brain. To determine the functional consequences of altered redox status, the study examined the dimerization status and enzymatic activity of the redox‐sensitive and neuron‐specific tyrosine phosphatase STEP (STriatal Enriched Phosphatase), a key regulator of synaptic signaling and neuroprotection. Results: The findings demonstrate that moderate PAE significantly reduces total thiol content and glutathione levels in adult male PAE offspring. This redox imbalance is accompanied by enhanced STEP dimerization and a concomitant reduction in STEP phosphatase activity. Notably, the redox imbalance and STEP dysfunction persisted into aging in male PAE offspring. Conclusions: These findings demonstrate that moderate PAE leads to long‐lasting alterations in the brain's redox homeostasis and compromises STEP function in male offspring. Such persistent dysfunction of the redox‐sensitive neuroprotectant STEP may increase the vulnerability of male PAE offspring to neurological disorders later in life. Future studies would examine sex‐ and age‐related interactions in PAE offspring.

  • Open Access

    Regulating the Impact of Hypertension on Stroke: Therapeutic Potential of a Peptide Mimetic of Tyrosine Phosphatase STEP

    by Seong W. Choi, Sathyanarayanan Rajagopal, Prabu Paramasivam, Ranjana Poddar, Surojit Paul

    Background: In spite of the advances in understanding the pathophysiology of stroke, successful treatment remains a major challenge. The lack of consideration of preclinical studies with associated comorbidities is a primary factor for the translational failure, as ~94% of patients with stroke have ≥1 preexisting comorbidities. Because hypertension is the most common comorbid condition in patients with stroke and predisposition to hypertension is known to worsen stroke outcome, we evaluated the efficacy of a novel neuroprotective peptide derived from the brain‐enriched and neuron‐specific tyrosine phosphatase striatal enriched phosphatase (STEP) in attenuating ischemic brain damage under hypertensive conditions. Methods: Mild ischemic insult was induced in hypertensive rats by middle cerebral artery occlusion for 60 minutes followed by reperfusion for 30 days. In a subset of hypertensive rats, the STEP‐mimetic peptide (STEP‐peptide) was administered intravenously 6 hours after the onset of the insult. Magnetic resonance imaging scans of the brain were done 1, 7, and 28 days after the insult to assess temporal evolution of ischemic brain damage. Behavioral studies were performed weekly starting 7 days after the onset of the insult. Histopathological staining of brain sections was done 30 days later. Results: The results show that delayed treatment with a single intravenous administration of the STEP‐peptide 6 hours after the onset of the insult reduces mortality rate. In the surviving rats, T2‐weighted imaging, and diffusion tensor imaging of the brain on post‐stroke days 1, 7, and 28 show significant reduction in infarct size and improvement of structural integrity within the infarcted area following treatment. Furthermore, behavioral studies show significant improvement in motor coordination, sensory motor function, and spatial memory over time. Conclusions: The efficacy of the novel STEP‐peptide in mitigating brain damage and improving functional recovery in a preclinical stroke model of hypertension holds promise for the development of potential strategies to treat acute ischemic stroke in the population with hypertension.


  • Open Access

    Impairment of neuronal tyrosine phosphatase STEP worsens post-ischemic inflammation and brain injury under hypertensive condition

    by Prabu Paramasivam, Seong Won Choi, Ranjana Poddar, Surojit Paul

    Hypertension is associated with poor outcome and higher mortality in patients with ischemic stroke. The impairment of adaptive vascular mechanisms under hypertensive condition compromises collateral blood flow after arterial occlusion in patients with acute ischemic stroke resulting in hypoperfusion. The increased oxidative stress caused by hypoperfusion is thought to be a trigger for the rapid evolution of ischemic infarct volume under hypertensive condition. However, the cellular factors and pathways that contribute to the exacerbation of ischemic brain injury under hypertensive condition is not yet understood. The current study reveals that predisposition to hypertension leads to basal loss of function of the neuron-specific tyrosine phosphatase STEP, which plays a crucial role in neuroprotection against excitotoxic insult. The findings further show that a mild ischemic insult in hypertensive rats triggers an early onset and sustained activation of the neuronal extracellular signal regulated kinase (ERK MAPK), a member of the mitogen activated protein kinase family and a substrate of STEP. This leads to rapid increase in the activation of neuronal NF-κB, expression of neuronal cyclooxygenase-2 and subsequent biosynthesis of the pro-inflammatory mediator prostaglandin E2, resulting in rapid morphological transformation of microglia to the pro-inflammatory state and subsequent exacerbation of ischemic brain injury. Restoration of STEP signaling with intravenous administration of a STEP-derived peptide mimetic reduces the pro-inflammatory response in neurons, activation of microglia, and ischemic brain injury. The findings suggest that the basal loss of STEP function under hypertensive condition contributes to the exacerbation of ischemic brain injury by enhancing post-ischemic inflammatory response. The study not only presents a novel role of STEP in regulating neuroimmune communication but also highlights the therapeutic potential of a STEP-mimetic in mitigating ischemic brain damage under hypertensive condition.


  • Regulation of post-ischemic inflammatory response: A novel function of the neuronal tyrosine phosphatase STEP

    by Sathyanarayanan Rajagopal, Changjun Yang, Kelly M. DeMars, Ranjana Poddar, Eduardo Candelario-Jalil, Surojit Paul


  • Striatal-Enriched Protein-Tyrosine Phosphatase (STEP)

    by Pradeep Kurup, Jian Xu, Manavi Chatterjee, Susan Goebel-Goody, Surojit Paul, Paul Lombroso

  • Open Access

    A peptide mimetic of tyrosine phosphatase STEP as a potential therapeutic agent for treatment of cerebral ischemic stroke

    by Ranjana Poddar, Sathyanarayanan Rajagopal, Lucas Winter, Andrea M Allan, Surojit Paul

    Extensive research over the last two decades has advanced our understanding of the pathophysiology of ischemic stroke. However, current pharmacologic therapies are still limited to rapid reperfusion using thrombolytic agents, and neuroprotective approaches that can reduce the consequences of ischemic and reperfusion injury, are still not available. To bridge this gap, we have evaluated the long-term efficacy and therapeutic time window of a novel peptide-based neuroprotectant TAT-STEP, derived from the brain-enriched and neuron-specific tyrosine phosphatase STEP. Using a rat model of transient middle cerebral artery occlusion (90 min), we show that a single intravenous administration of the peptide at the onset of reperfusion (early) or 6 h after the onset of the insult (delayed) reduces mortality rate. In the surviving rats, MRI scans of the brain at days 1, 14 and 28 after the insult show significant reduction in infarct size and improvement of structural integrity within the infarcted area following peptide treatment, regardless of the time of administration. Behavioral assessments show significant improvement in normal gait, motor coordination, sensory motor function and spatial memory following early or delayed peptide treatment. The study establishes for the first time the therapeutic potential of a tyrosine phosphatase in ischemic brain injury.


  • Striatal-Enriched Protein-Tyrosine Phosphatase (STEP)

    by Pradeep Kurup, Jian Xu, Manavi Chatterjee, Susan Goebel-Goody, Surojit Paul, Paul Lombroso